B. Riley Securities Reiterates Neutral on Madrigal Pharmaceuticals, Maintains $224 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani has reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $224.
September 11, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Madrigal Pharmaceuticals' stock rating has been reiterated as Neutral by B. Riley Securities, with a maintained price target of $224.
The reiteration of a Neutral rating indicates that the analyst believes the stock will perform in line with the market average. This is neither a negative nor a positive signal for investors, hence the neutral score. The maintained price target suggests that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100